+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Pharmaceutical & Healthcare Annual Deals Analysis: M&A and Investments Trends - 2019

  • PDF Icon

    Report

  • 154 Pages
  • March 2020
  • Region: Global
  • GlobalData
  • ID: 5024207
Pharmaceutical & Healthcare Annual Deals Analysis: M&A and Investments Trends - 2019

Summary

“Pharmaceutical & Healthcare Annual Deals Analysis: M&A and Investments Trends - 2019” report is an essential source of data and trend analysis on partnerships, licensing, mergers and acquisitions (M&As) and financings in the pharmaceuticals industry. The report provides detailed information on partnership and licensing transactions, M&As, equity/debt offerings, private equity, and venture financing registered in the pharmaceuticals industry in the year 2019. The report portrays detailed comparative data on the number of deals and their value in the last five years, subdivided by deal types, various therapy areas, and geographies. Additionally, the report provides information on the top financial advisory firms in the pharmaceuticals industry.
Data presented in this report is derived from the publisher's proprietary in-house Pharmaceuticals eTrack deals database and primary and secondary research.

Scope

  • Analysis of the market trends for the pharmaceutical industry in the global arena.
  • Review of deal trends in the cardiovascular, central nervous system, dermatology, ear nose throat disorders, gastrointestinal, genito urinary system and sex hormones, hematological disorders, hormonal disorders, immunology, infectious disease, male health, metabolic disorders, mouth and dental disorders, musculoskeletal, oncology, ophthalmology, respiratory, toxicology, and women's health segments.
  • Analysis of partnerships, licensing, M&As, equity/debt offerings, private equity, and venture financing deals in the pharmaceutical industry.
  • Analysis of therapy areas which are very active in terms of venture capital financing, partnerships, licensing agreements, equity/debt offerings, and M&As.
  • Analysis of deals based on different payment modes, including upfront and milestone payments, primarily in partnerships and licensing agreements in the pharmaceutical industry.
  • Analysis of partnership and licensing deals based on clinical stage of development of products.
  • Summary of the pharmaceutical deals globally in the six months.
  • Information on the top deals happened in the pharmaceutical industry.
  • Geographies covered include - North America, Europe, Asia Pacific, South & Central America, and the Middle East & Africa.
  • League tables of financial advisors in M&As and equity/debt offerings. This includes key advisors such as Morgan Stanley, Credit Suisse, and Goldman Sachs.

Reasons to Buy

  • Enhance your decision making capability in a more rapid and time sensitive manner.
  • Find out the major deal performing segments for investments in your industry.
  • Evaluate the types of companies which are entering into partnership or licensing agreements; divesting and acquiring assets.
  • Identify companies that are aggressively looking to raise capital in the market
  • Evaluate niche therapy areas that are receiving majority of the upfront and milestone payments in the pharmaceutical industry.
  • Identify the key venture capitalists, who are financing the pharmaceutical and biotech companies.
  • Evaluate the clinical development stages where majority of the partnerships and licensing agreements are happening.
  • Do deals with an understanding of how competitors are financed, and the mergers and partnerships that have shaped the pharmaceutical industry.
  • Identify growth segments and opportunities in each region within the industry.
  • Look for key financial advisors where you are planning to raise capital from the market or for acquisitions within the industry.

Table of Contents

1. Table of Contents
List of Tables
List of Figures
2. Deal Values In Pharmaceutical & Healthcare Industry Increased In 2019
2.1. Pharmaceutical & Healthcare, Deals Summary, 2019
3. Pharmaceutical & Healthcare, Global, Deals Summary
3.1. Pharmaceutical & Healthcare, Global, Deals Analysis, 2019
3.1.1. Pharmaceuticals & Healthcare, Global, Deals Analysis, 2019 by Quarter
3.2. Pharmaceuticals & Healthcare, Global, by Type, Number of Deals, 2019
3.3. Pharmaceuticals & Healthcare, Global, by Type, Deal Values, 2019
3.4. Pharmaceuticals & Healthcare, Global, Top Deals, 2019
3.5. Pharmaceuticals & Healthcare, Top Deals, Global, Summaries, 2019
3.5.1. Shire Bristol-Myers Squibb Acquires Celgene
3.5.2. AbbVie to Acquire Allergan
3.5.3. AbbVie Raises USD30 Billion in Private Placement of Notes
3.5.4. Danaher to Acquire Biopharma Business from General Electric for USD21.4 Billion
3.5.5. Bristol-Myers Squibb Raises USD19 Billion in Private Placement of Notes
3.5.6. Amgen Acquires Rights to Otezla from Celgene for USD13.4 Billion
3.5.7. Pfizer Acquires Array BioPharma
3.5.8. Consortium of Investors Acquire Nestle Skin Health from Nestle for USD10.11 Billion
3.5.9. Novartis Acquires Medicines Co
3.5.10. Eli Lilly Acquires Loxo Oncology for USD8 Billion
4. Pharmaceuticals & Healthcare, Global, Deal Summary, by Type5. Pharmaceuticals & Healthcare, Global, Deal Summary, By Market6. Pharmaceuticals & Healthcare, Deal Summary, By Geography
7. Pharmaceuticals & Healthcare, Global, Top Financial Advisors
7.1. Pharmaceuticals & Healthcare, Global, Top Financial Advisors, M&A, 2019
7.2. Pharmaceuticals & Healthcare, Global, Top Financial Advisors, Equity Offerings, 2019
8. Further Information
8.1. Methodology
8.2. About the Publisher
8.3. Contact the Publisher
8.4. Disclosure information
8.5. Disclaimer
List of Tables
Table 1: Pharmaceutical & Healthcare, Global, Deals Summary, Number of Deals and Deal Value (US$ m), 2015 - 2019
Table 2: Pharmaceuticals & Healthcare, Deals Summary, Global, Number of Deals and Deal Value (US$ m), Q1 2019-Q4 2019
Table 3: Pharmaceuticals & Healthcare, Global, Number Of Deals and Deal Values (%), 2019
Table 4: Pharmaceuticals & Healthcare, Top Deals, Global, 2019
Table 5: Pharmaceuticals & Healthcare, Global, M&A, Deals Summary, Number of Deals and Deal Values (US$ m), 2015 - 2019
Table 6: Pharmaceuticals & Healthcare, Global, M&A, Deals Summary, Number of Deals and Deal Values (US$ m), Q1 2019-Q4 2019
Table 7: Pharmaceuticals & Healthcare, Global, Top M&A Deals, 2019
Table 8: Pharmaceuticals & Healthcare, Global, M&A, Deals Summary, Number of Deals and Deal Values (US$ m), by Therapy Area, 2019
Table 9: Pharmaceuticals & Healthcare, Global, Equity Offerings, Deals Summary, Number of Deals and Deal Values (US$ m), 2015 - 2019
Table 10: Pharmaceuticals & Healthcare, Global, Equity Offerings, Deals Summary, Number of Deals and Deal Values (US$ m), Q1 2019-Q4 2019
Table 11: Pharmaceuticals & Healthcare, Global, IPO Deals, Deals Summary, Number of Deals and Deal Value (US$ m), 2015 - 2019
Table 12 Pharmaceuticals & Healthcare, Global, Top IPOs, 2019
Table 13: Pharmaceuticals & Healthcare, Global, Secondary Offerings, Deals Summary, Number of Deals and Deal Value (US$ m), 2015 - 2019
Table 14: Pharmaceuticals & Healthcare, Global, Top Secondary Offerings, 2019
Table 15: Pharmaceuticals & Healthcare, Global, PIPEs, Deals Summary, Number of Deals and Deal Value (US$ m), 2015 - 2019
Table 16: Pharmaceuticals & Healthcare, Global, Top PIPE Deals, 2019
Table 17: Pharmaceuticals & Healthcare, Global, Equity Offering Deals, Deals Summary, Number of Deals and Deal Values (US$ m), 2019
Table 18: Pharmaceuticals & Healthcare, Global, Debt Offering, Deals Summary, Number of Deals and Deal Values (US$ m), 2015 - 2019
Table 19: Pharmaceuticals & Healthcare, Global, Debt Offering, Deals Summary, Number of Deals and Deal Values (US$ m), Q1 2019-Q4 2019
Table 20: Pharmaceuticals & Healthcare, Global, Public Debt Offerings, Deals Summary, Number of Deals and Deal Value (US$ m), 2015 - 2019
Table 21: Pharmaceuticals & Healthcare, Global, Top Public Debt Offerings, 2019
Table 22: Pharmaceuticals & Healthcare, Global, Private Debt Placements, Deals Summary, Number of Deals and Deal Value (US$ m), 2015 - 2019
Table 23: Pharmaceuticals & Healthcare, Global, Top Private Debt Placements, 2019
Table 24: Pharmaceuticals & Healthcare, Global, Debt Offering Deals, Summary, Number of Deals and Deal Values (US$ m), 2019
Table 25: Pharmaceuticals & Healthcare, Global, Partnerships, Number of Deals and Deal Values (US$ m), 2015 - 2019
Table 26: Pharmaceuticals & Healthcare, Global, Partnerships, Number of Deals and Deal Values (US$ m), Q1 2019-Q4 2019
Table 27: Pharmaceuticals & Healthcare, Global, Partnership Deals, by Therapy Area, Number of Deals and Deal Values (US$ m), 2019
Table 28: Pharmaceuticals & Healthcare, Partnership Deals, Upfront & Milestone Payment and Deal Values (US$ m), 2019
Table 29: Pharmaceuticals & Healthcare, Global, Partnership Deals, by Therapy Area, Upfront & Milestone Payment and Deal Values (US$ m), 2019
Table 30: Pharmaceuticals & Healthcare, Global, Partnership Deals, by Phase, 2019
Table 31: Pharmaceuticals & Healthcare, Global, Partnership Deals, by Upfront & Milestone Payment and Deal Values (US$ m), 2019
Table 32: Pharmaceuticals & Healthcare, Global, Partnerships, Upfront & Milestone Payment and Deal Values (US$ m), 2019
Table 33: Pharmaceuticals & Healthcare, Global, Top Partnership Deals, by Upfront Payment, 2019
Table 34: Pharmaceuticals & Healthcare, Global, Top Partnership Deals, by Milestone Payment, 2019
Table 35: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, Deals Summary, Number of Deals and Deal Values (US$ m), 2015 - 2019
Table 36: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, Deals Summary, Number of Deals and Deal Values (US$ m), Q1 2019-Q4 2019
Table 37: Pharmaceuticals & Healthcare, Global, Licensing Agreements, by Therapy Area, Number of Deals and Deal Values (US$ m), 2019
Table 38: Pharmaceuticals & Healthcare, Licensing Agreements, Upfront & Milestone Payments and Deal Values (US$ m), 2019
Table 39: Pharmaceuticals & Healthcare, Global, Licensing Agreements, by Therapy Area, Upfront & Milestone Payments and Deal Values (US$ m), 2019
Table 40: Pharmaceuticals & Healthcare, Global, Partnership Deals, by Phase, Q4 2015 - Q4 2019
Table 41: Pharmaceuticals & Healthcare, Global, Licensing Agreements, by Upfront & Milestone Payments and Deal Values (US$ m), 2019
Table 42: Pharmaceuticals & Healthcare, Global, Partnerships, Upfront & Milestone Payment and Deal Values (US$ m), 2019
Table 43: Pharmaceuticals & Healthcare, Global, Top Licensing Agreements, by Upfront Payment, 2019
Table 44: Pharmaceutical & Healthcare, Global, Top Licensing Agreements, by Milestone Payment, 2019
Table 45: Pharmaceuticals & Healthcare, Global, Private Equity, Deals Summary, Number of Deals and Deal Values (US$ m), 2015 - 2019
Table 46: Pharmaceuticals & Healthcare, Global, Private Equity, Deals Summary, Number of Deals and Deal Values (US$ m), Q1 2019-Q4 2019
Table 47: Pharmaceuticals & Healthcare, Global, Top Private Equity Deals, 2019
Table 48: Pharmaceuticals & Healthcare, Global, Private Equity Deals, by Therapy Area, Deals Summary, Number of Deals and Deal Values (US$ m), 2019
Table 49: Pharmaceuticals & Healthcare, Global, Venture Capital, Deals Summary, Number of Deals and Deal Values (US$ m), 2015 - 2019
Table 50: Pharmaceuticals & Healthcare, Global, Venture Capital, Deals Summary, Number of Deals and Deal Values (US$ m), Q1 2019-Q4 2019
Table 51: Pharmaceuticals & Healthcare, Global, Venture Capital Deals, by Stage of Financing, Number Of Deals and Deal Values (%), 2019
Table 52: Pharmaceuticals & Healthcare, Global, Venture Capital Deals, by Therapy Area, Deals Summary, Number of Deals and Deal Values (US$ m), 2019
Table 53: Pharmaceutical & Healthcare, Global, Top VC Backed Companies, 2019
Table 54: Pharmaceuticals & Healthcare, Top Venture Financing Firms, Global, Number of Deals and Deal Value (US$ m), 2019
Table 55: Pharmaceuticals & Healthcare, Top Venture Financing Deals, Global, 2019
Table 56: Pharmaceuticals & Healthcare, Global, Oncology, Deals Summary, Number of Deals and Deal Values (US$ m), 2015 - 2019
Table 57: Pharmaceuticals & Healthcare, Global, Oncology, Deals Summary, Number of Deals and Deal Values (US$ m), Q1 2019-Q4 2019
Table 58: Pharmaceuticals & Healthcare, Global, Central Nervous System, Deals Summary, Number of Deals and Deal Values (US$ m), 2015 - 2019
List of Figures
Figure 1: Pharmaceutical & Healthcare, Number of Deals, 2015-2019
Figure 2: Pharmaceutical & Healthcare, Number of Deals by Type, 2015-2019
Figure 3: Pharmaceutical & Healthcare, Number of Deals by Therapy Area, 2019
Figure 4: Pharmaceutical & Healthcare, Number of Deals by Region, 2019
Figure 5: Pharmaceutical & Healthcare, Global, Number of Deals and Deal Value (US$ m), 2015- 2019
Figure 6: Pharmaceuticals & Healthcare, Global, Number of Deals and Deal Value (US$ m), Q1 2019-Q4 2019
Figure 7: Pharmaceuticals & Healthcare, Global, Number Of Deals (%), 2019
Figure 8: Pharmaceuticals & Healthcare, Global, Deal Values (%), 2019
Figure 9 Pharmaceuticals & Healthcare, Global, M&A, Number of Deals and Deal Values (US$ m), 2015 - 2019
Figure 10 Pharmaceuticals & Healthcare, Global, M&A, Number of Deals and Deal Values (US$ m), Q1 2019-Q4 2019
Figure 11: Pharmaceuticals & Healthcare, Global, M&As, by Therapy Area, Number of Deals and Deal Values (US$ m), by Therapy Area, 2019
Figure 12: Pharmaceuticals & Healthcare, Global, Equity Offering Deals, Number of Deals and Deal Values (US$ m), 2015 - 2019
Figure 13: Pharmaceuticals & Healthcare, Global, Equity Offering Deals, Number of Deals and Deal Values (US$ m), Q1 2019-Q4 2019
Figure 14: Pharmaceuticals & Healthcare, Global, IPO Deals, Number of Deals and Deal Value (US$ m), 2015 - 2019
Figure 15: Pharmaceuticals & Healthcare, Global, Secondary Offerings Deals, Number of Deals and Deal Value (US$ m), 2015 - 2019
Figure 16: Pharmaceuticals & Healthcare, Global, PIPE Deals, Number of Deals and Deal Value (US$ m), 2015 - 2019
Figure 17: Pharmaceuticals & Healthcare, Global, Equity Offering Deals, by Therapy Area, Number of Deals and Deal Values (US$ m), 2019
Figure 18: Pharmaceuticals & Healthcare, Global, Debt Offering Deals, Number of Deals and Deal Values (US$ m), 2015 - 2019
Figure 19: Pharmaceuticals & Healthcare, Global, Debt Offering Deals, Number of Deals and Deal Values (US$ m), Q1 2019-Q4 2019
Figure 20: Pharmaceuticals & Healthcare, Global, Public Debt Offering Deals, Number of Deals and Deal Value (US$ m), 2015 - 2019
Figure 21: Pharmaceuticals & Healthcare, Global, Private Debt Placements, Number of Deals and Deal Value (US$ m), 2015 - 2019
Figure 22: Pharmaceuticals & Healthcare, Global, Debt Offering Deals, by Therapy Area, Number of Deals and Deal Values (US$ m), 2019
Figure 23: Pharmaceuticals & Healthcare, Global, Partnerships, Number of Deals and Deal Values (US$ m), 2015 - 2019
Figure 24: Pharmaceuticals & Healthcare, Global, Partnerships, Number of Deals and Deal Values (US$ m), Q1 2019-Q4 2019
Figure 25: Pharmaceuticals & Healthcare, Global, Partnership Deals Break down (%), 2019
Figure 26: Pharmaceuticals & Healthcare, Global, Partnership Deals, by Therapy Area, Number of Deals and Deal Values (US$ m), 2019
Figure 27: Pharmaceuticals & Healthcare, Global, Partnership Deals, Upfront & Milestone Payments and Deal Values (US$ m), 2019
Figure 28: Pharmaceuticals & Healthcare, Global, Partnership Deals, by Therapy Area, Upfront & Milestone Payment and Deal Values (US$ m), 2019
Figure 29: Pharmaceuticals & Healthcare, Global, Partnership Deals, by Phase, 2019
Figure 30: Pharmaceuticals & Healthcare, Global, Partnership Deals, by Phase, 2019
Figure 31: Pharmaceuticals & Healthcare, Global, Partnership Deals, by Phase, by Upfront & Milestone Payments and Deal Values (US$ m), 2019
Figure 32: Pharmaceuticals & Healthcare, Global, Licensing Agreements, Number of Deals and Deal Values (US$ m), 2015 - 2019
Figure 33: Pharmaceuticals & Healthcare, Global, Licensing Agreements, Number of Deals and Deal Values (US$ m), Q1 2019-Q4 2019
Figure 34: Pharmaceuticals & Healthcare, Global, Licensing Agreements, by Therapy Area, Number of Deals and Deal Values (US$ m), 2019
Figure 35: Pharmaceuticals & Healthcare, Global, Licensing Agreements, Upfront & Milestone Payments and Deal Values (US$ m), 2019
Figure 36: Pharmaceuticals & Healthcare, Global, Licensing Agreements, by Therapy Area, Upfront & Milestone Payment and Deal Values (US$ m), 2019
Figure 37: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, by Phase, Number Of Deals, 2019
Figure 38: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, by Phase, Deal Values (US$ m), 2019
Figure 39: Pharmaceuticals & Healthcare, Global, Licensing Agreements, by Phase, by Upfront & Milestone Payment and Deal Values (US$ m), 2019
Figure 40: Pharmaceuticals & Healthcare, Global, Private Equity, Number of Deals and Deal Values (US$ m), 2015 - 2019
Figure 41: Pharmaceuticals & Healthcare, Global, Private Equity, Number of Deals and Deal Values (US$ m), Q1 2019-Q4 2019
Figure 42: Pharmaceuticals & Healthcare, Global, Private Equity Deals, by Therapy Area, Number of Deals and Deal Values (US$ m), by Therapy Area, 2019
Figure 43: Pharmaceuticals & Healthcare, Global, Venture Capital, Number of Deals and Deal Values (US$ m), 2015 - 2019
Figure 44: Pharmaceuticals & Healthcare, Global, Venture Capital, Number of Deals and Deal Values (US$ m), Q1 2019-Q4 2019
Figure 45: Pharmaceuticals & Healthcare, Global, Venture Capital Deals, by Stage of Financing, Number Of Deals (%), 2019
Figure 46: Pharmaceuticals & Healthcare, Global, Venture Capital Deals, by Stage of Financing, Deal Values (%), 2019
Figure 47: Pharmaceuticals & Healthcare, Global, Venture Capital Deals, by Therapy Area, Number of Deals and Deal Values (US$ m), by Therapy Area, 2019
Figure 48: Pharmaceuticals & Healthcare, Top Venture Financing Firms, Global, Number of Deals and Deal Value (US$ m), 2019
Figure 49: Pharmaceuticals & Healthcare, Global, Oncology, Number of Deals and Deal Values (US$ m), 2015 - 2019
Figure 50: Pharmaceuticals & Healthcare, Global, Oncology, Number of Deals and Deal Values (US$ m), Q1 2019-Q4 2019
Figure 51: Pharmaceuticals & Healthcare, Global, Central Nervous System, Number of Deals and Deal Values (US$ m), 2019, 2015 - 2019
Figure 52: Pharmaceuticals & Healthcare, Central Nervous System, Number of Deals and Deal Values (US$ m), Q1 2019-Q4 2019
Figure 53: Pharmaceuticals & Healthcare, Global, Infectious Disease, Number of Deals and Deal Value (US$ m), 2015 - 2019
Figure 54: Pharmaceuticals & Healthcare, Global, Infectious Disease, Number of Deals and Deal Value (US$ m), Q1 2019-Q4 2019
Figure 55: Pharmaceuticals & Healthcare, Global, Immunology, Number of Deals and Deal Values (US$ m), 2015 - 2019
Figure 56: Pharmaceuticals & Healthcare, Global, Immunology, Number of Deals and Deal Values (US$ m), Q1 2019-Q4 2019
Figure 57: Pharmaceuticals & Healthcare, Global, Cardiovascular, Number of Deals and Deal Values (US$ m), 2015 - 2019
Figure 58: Pharmaceuticals & Healthcare, Global, Cardiovascular, Number of Deals and Deal Values (US$ m), Q1 2019-Q4 2019
Figure 59: Pharmaceuticals & Healthcare, Global, Metabolic Disorders, Number of Deals and Deal Values (US$ m), 2015 - 2019
Figure 60: Pharmaceuticals & Healthcare, Global, Metabolic Disorders, Number of Deals and Deal Values (US$ m), Q1 2019-Q4 2019